-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$21.50329.14% Upside
Verve Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Verve Therapeutics, Inc.?
Verve Therapeutics, Inc. has been rated by research analysts at BMO Capital, Goldman Sachs in the past 90 days.